Telephone
61.3.9824.5254
Address
Level 3 62 Lygon Street Carlton, Victoria (VIC) 3053
Description
Imugene Ltd. is a biopharmaceutical company, which engages in the research, development, and commercialisation of health technologies against cancer. Its products include b-cell peptide cancer vaccines, arginine modulators, and mimotopes. The company was founded on May 30, 1986 and is headquartered in Sydney, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.04 - 0.2
Trade Value (12mth)
AU$624,383.00
1 week
25%
1 month
150%
YTD
-27.59%
1 year
-43.24%
All time high
0.625
EPS 3 yr Growth
130.800%
EBITDA Margin
N/A
Operating Cashflow
-$30m
Free Cash Flow Return
-18.10%
ROIC
-23.00%
Interest Coverage
-1,788.10
Quick Ratio
27.20
Shares on Issue (Fully Dilluted)
6423m
HALO Sector
Healthcare
Next Company Report Date
30-Aug-24
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
6.96
Date | Announcements |
---|---|
31 October 23 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
31 October 23 |
Amended Annual Report
×
Amended Annual Report |
31 October 22 |
First patient dosed in VAXINIA intratumoral cohort 2
×
First patient dosed in VAXINIA intratumoral cohort 2 |
31 October 22 |
Imugene Limited - First patient dosed in VAXINIA intratumoral cohort 2 (IMU-AU)
×
Imugene Limited - First patient dosed in VAXINIA intratumoral cohort 2 (IMU-AU) |
31 May 22 |
IMUGENE PUBLICATION OF CHECKVACC ABSTRACT AT ASCO 2022
×
IMUGENE PUBLICATION OF CHECKVACC ABSTRACT AT ASCO 2022 |
31 May 22 |
Imugene Limited - IMUGENE PUBLICATION OF CHECKVACC ABSTRACT AT ASCO 2022 (IMU-AU)
×
Imugene Limited - IMUGENE PUBLICATION OF CHECKVACC ABSTRACT AT ASCO 2022 (IMU-AU) |
31 January 22 |
Oncolytic Virotherapy CF33 Patent Granted in Japan
×
Oncolytic Virotherapy CF33 Patent Granted in Japan |
31 January 22 |
Issue of Options under the Employee Share Option Plan
×
Issue of Options under the Employee Share Option Plan |
31 January 22 |
Imugene Limited - Oncolytic Virotherapy CF33 Patent Granted in Japan (IMU-AU)
×
Imugene Limited - Oncolytic Virotherapy CF33 Patent Granted in Japan (IMU-AU) |
31 January 22 |
Imugene Limited - Issue of Options under the Employee Share Option Plan (IMU-AU)
×
Imugene Limited - Issue of Options under the Employee Share Option Plan (IMU-AU) |
31 August 22 |
Annual Report and Appendix 4E
×
Annual Report and Appendix 4E |
31 August 22 |
Appendix 4G
×
Appendix 4G |
31 August 22 |
Corporate Governance Statement
×
Corporate Governance Statement |
31 August 22 |
Environmental Social and Governance (ESG) Report
×
Environmental Social and Governance (ESG) Report |
31 August 22 |
Imugene Limited - Annual Report and Appendix 4E (IMU-AU)
×
Imugene Limited - Annual Report and Appendix 4E (IMU-AU) |
31 August 22 |
Imugene Limited - Appendix 4G (IMU-AU)
×
Imugene Limited - Appendix 4G (IMU-AU) |
31 August 22 |
Imugene Limited - Corporate Governance Statement (IMU-AU)
×
Imugene Limited - Corporate Governance Statement (IMU-AU) |
31 August 22 |
Imugene Limited - Environmental Social and Governance (ESG) Report (IMU-AU)
×
Imugene Limited - Environmental Social and Governance (ESG) Report (IMU-AU) |
31 August 20 |
Appendix 4E & Annual Report to shareholders
×
Appendix 4E & Annual Report to shareholders |
31 August 20 |
Imugene Limited - Appendix 4E & Annual Report to shareholders (IMU-AU)
×
Imugene Limited - Appendix 4E & Annual Report to shareholders (IMU-AU) |
31 August 17 |
Appendix 4E and Annual Report
×
Appendix 4E and Annual Report |
31 August 15 |
Appendix 4E and Annual Report 2015
×
Appendix 4E and Annual Report 2015 |
30 September 16 |
Notice of Annual General Meeting/Proxy Form
×
Notice of Annual General Meeting/Proxy Form |
30 October 23 |
Notice of Annual General Meeting/Proxy Form
×
Notice of Annual General Meeting/Proxy Form |
30 November 23 |
AGM Presentation
×
AGM Presentation |
30 November 23 |
Results of Meeting
×
Results of Meeting |
30 November 12 |
CTO Presentation
×
CTO Presentation |
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.